Kewaunee Scientific Co. (NASDAQ:KEQU) CEO Thomas David Hull III Sells 213 Shares

Kewaunee Scientific Co. (NASDAQ:KEQU - Get Free Report) CEO Thomas David Hull III sold 213 shares of the firm's stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $48.53, for a total value of $10,336.89. Following the sale, the chief executive officer now directly owns 40,916 shares of the company's stock, valued at $1,985,653.48. This trade represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Thomas David Hull III also recently made the following trade(s):

• On Monday, March 24th, Thomas David Hull III sold 3,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $45.63, for a total value of $136,890.00.
• On Friday, January 10th, Thomas David Hull III sold 1,368 shares of Kewaunee Scientific stock. The shares were sold at an average price of $60.08, for a total transaction of $82,189.44.
• On Thursday, December 26th, Thomas David Hull III sold 2,000 shares of Kewaunee Scientific stock. The stock was sold at an average price of $63.01, for a total transaction of $126,020.00.

Kewaunee Scientific Stock Performance

Shares of KEQU stock traded down $2.68 during trading on Friday, reaching $39.82. The company had a trading volume of 22,197 shares, compared to its average volume of 22,874. The firm's 50 day simple moving average is $56.22 and its two-hundred day simple moving average is $47.47. Kewaunee Scientific Co. has a one year low of $30.82 and a one year high of $71.33. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.64 and a quick ratio of 2.13. The company has a market capitalization of $113.69 million, a PE ratio of 6.31 and a beta of 0.71.

Remove Ads

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The technology company reported $1.09 earnings per share for the quarter. Kewaunee Scientific had a net margin of 9.39% and a return on equity of 25.83%. The business had revenue of $67.17 million during the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Kewaunee Scientific from a "buy" rating to a "hold" rating in a report on Friday, March 14th.

Institutional Investors Weigh In On Kewaunee Scientific

A number of hedge funds have recently bought and sold shares of KEQU. De Lisle Partners LLP increased its stake in shares of Kewaunee Scientific by 36.6% in the third quarter. De Lisle Partners LLP now owns 42,958 shares of the technology company's stock worth $1,446,000 after purchasing an additional 11,511 shares during the period. State Street Corp bought a new position in Kewaunee Scientific in the 3rd quarter worth approximately $266,000. Barclays PLC bought a new position in Kewaunee Scientific in the 3rd quarter worth approximately $121,000. Geode Capital Management LLC lifted its holdings in shares of Kewaunee Scientific by 8.9% during the third quarter. Geode Capital Management LLC now owns 23,784 shares of the technology company's stock worth $792,000 after buying an additional 1,941 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Kewaunee Scientific by 18,000.0% in the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock valued at $30,000 after acquiring an additional 900 shares during the period. 32.69% of the stock is currently owned by institutional investors.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.